Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2020 from OUS - Section for sarcoma and melanoma

14 publications found

Dagenborg VJ, Marshall SE, Yaqub S, Grzyb K, Boye K, Lund-Iversen M, Høye E, Berstad AE, Fretland ÅA, Edwin B, Ree AH, Flatmark K (2020)
Neoadjuvant chemotherapy is associated with a transient increase of intratumoral T-cell density in microsatellite stable colorectal liver metastases
Cancer Biol Ther, 21 (5), 432-440
DOI 10.1080/15384047.2020.1721252, PubMed 32098573

Fauske L, Hompland I, Lorem G, Hall KS, Bondevik H (2020)
Striving towards Normality in Daily Life: A Qualitative Study of Patients Living with Metastatic Gastrointestinal Stromal Tumour in Long-Term Clinical Remission
Sarcoma, 2020, 1814394
DOI 10.1155/2020/1814394, PubMed 33082706

Flem-Karlsen K, Nyakas M, Farstad IN, McFadden E, Wernhoff P, Jacobsen KD, Flørenes VA, Mælandsmo GM (2020)
Soluble AXL as a marker of disease progression and survival in melanoma
PLoS One, 15 (1), e0227187
DOI 10.1371/journal.pone.0227187, PubMed 31917795

Fleten KG, Lund-Andersen C, Waagene S, Abrahamsen TW, Mørch Y, Boye K, Torgunrud A, Flatmark K (2020)
Experimental Treatment of Mucinous Peritoneal Metastases Using Patient-Derived Xenograft Models
Transl Oncol, 13 (8), 100793
DOI 10.1016/j.tranon.2020.100793, PubMed 32447231

Georgiesh T, Boye K, Bjerkehagen B (2020)
A novel risk score to predict early and late recurrence in solitary fibrous tumour
Histopathology, 77 (1), 123-132
DOI 10.1111/his.14078, PubMed 31991494

Hompland I, Fauske L, Lorem GF, Bruland ØS (2020)
Use of a simple form to facilitate communication on long-term consequences of treatment in sarcoma survivors
Clin Sarcoma Res, 10, 2
DOI 10.1186/s13569-019-0124-3, PubMed 31969978

Janssens GO, Melchior P, Mul J, Saunders D, Bolle S, Cameron AL, Claude L, Gurtner K, van de Ven KP, van Grotel M, Harrabi S, Lassen-Ramshad Y, Lavan N, Magelssen H, Muracciole X, Boterberg T, Mandeville H, Godzinski J, Graf N, van den Heuvel-Eibrink MM, Rübe C (2020)
The SIOP-Renal Tumour Study Group consensus statement on flank target volume delineation for highly conformal radiotherapy
Lancet Child Adolesc Health, 4 (11), 846-852
DOI 10.1016/S2352-4642(20)30183-8, PubMed 33068550

König M, Osnes T, Bruland Ø, Sundby Hall K, Bratland Å, Meling TR (2020)
The Role of Adjuvant Treatment in Craniofacial Malignancy: A Critical Review
Front Oncol, 10, 1402
DOI 10.3389/fonc.2020.01402, PubMed 32850452

Napoli E, Stenberg VY, Juzeniene A, Hjellum GE, Bruland ØS, Larsen RH (2020)
Calibration of sodium iodide detectors and reentrant ionization chambers for 212Pb activity in different geometries by HPGe activity determined samples
Appl Radiat Isot, 166, 109362 (in press)
DOI 10.1016/j.apradiso.2020.109362, PubMed 32979756

Nilsen LB, Digernes I, Grøvik E, Saxhaug C, Latysheva A, Geier O, Breivik B, Sætre DO, Jacobsen KD, Helland Å, Emblem KE (2020)
Responses in the diffusivity and vascular function of the irradiated normal brain are seen up until 18 months following SRS of brain metastases
Neurooncol Adv, 2 (1), vdaa028
DOI 10.1093/noajnl/vdaa028, PubMed 32642687

Palmerini E, Leithner A, Windhager R, Gosheger G, Boye K, Laitinen M, Hardes J, Traub F, Jutte P, Willegger M, Casanova J, Setola E, Righi A, Picci P, Donati DM, Ferrari S (2020)
Angiosarcoma of bone: a retrospective study of the European Musculoskeletal Oncology Society (EMSOS)
Sci Rep, 10 (1), 10853
DOI 10.1038/s41598-020-66579-5, PubMed 32616718

Ree AH, Nygaard V, Boye K, Heinrich D, Dueland S, Bergheim IR, Johansen C, Beiske K, Negård A, Lund-Iversen M, Nygaard V, Hovig E, Nakken S, Nasser S, Julsrud L, Reisse CH, Ruud EA, Kristensen VN, Flørenes VA, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Russnes HG, Mælandsmo GM, Flatmark K (2020)
Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study
Acta Oncol, 59 (7), 733-740
DOI 10.1080/0284186X.2020.1742377, PubMed 32208873

Stenberg VY, Juzeniene A, Bruland ØS, Larsen RH (2020)
In situ Generated 212Pb-PSMA Ligand in a 224Ra-Solution for Dual Targeting of Prostate Cancer Sclerotic Stroma and PSMA-positive Cells
Curr Radiopharm, 13 (2), 130-141
DOI 10.2174/1874471013666200511000532, PubMed 32389119

Stenberg VY, Juzeniene A, Chen Q, Yang X, Bruland ØS, Larsen RH (2020)
Preparation of the alpha-emitting prostate-specific membrane antigen targeted radioligand [212 Pb]Pb-NG001 for prostate cancer
J Labelled Comp Radiopharm, 63 (3), 129-143
DOI 10.1002/jlcr.3825, PubMed 31919866

 
Page visits: 454014